From: Immune related biomarkers for cancer metastasis to the brain
Primary Cancer | No | Treatment | Biomarker | Method | Sample type | Cut-off | HR | CI | P | Follow up | Prognosis | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Breast Cancer | 84 | No | PD-1 | IHC | Tissue | 0.10% | 0.3 | NR |  < 0.003 | 21 mos | Longer OS | [117] |
Multiple cancer* | 236 | No | CD74 | Microarray | Tissue | Score > 20 | NR | NR | 0.001 | 4166 days | Longer OS | [119] |
Breast Cancer | 20 | NO | Vista | IHC | Tissue | NR | NR | NR | NR | NR | NR | [123] |
SCLC | 32 | No | PD-L1 | IHC | Tissue | 5% | NR | NR | 0.002 | NR | Longer OS | [126] |
NSCLC | 34 | ICI | PD-L1 | FACS | Tissue/blood | Median | NR | 7.8–NR | 0.003 | 1200 days | Worse OS | [127] |
NSCLC | 49 | No | B7-H4 | IHC | Tissue | Median | NR | NR | 0.002 | 14 mons | Worse OS | [131] |